BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
See today's BioWorld
Home
» Potential $285M: Ipsen and Active Biotech in TASQ Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Potential $285M: Ipsen and Active Biotech in TASQ Deal
April 19, 2011
By
Cormac Sheridan
No Comments
Active Biotech AB is banking an up-front payment of $35.6 million and could get $249.4 million more on the back of a partnering deal with Ipsen SA on its Phase III cancer drug tasquinimod (TASQ).
BioWorld